EZI)(OTCQXNZZF) today announced that its licensee, Fukuda Denshi, has received FDA and UKCA approvals to launch its integrated HN-100 neuromuscular transmission module in the US and UK markets. The HN-100 module, powered by Senzime's TetraGraph\u00ae technology, is the first stand-alone electromyography (EMG)-based solution designed for plug-and-play integration with Fukuda Denshi's line of bedside patient monitors. 